Targeted Drug Delivery Partnering 2009-2014 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.
Trends in targeted drug delivery partnering deals
- Top Targeted deals by value
- Deals listed by company A-Z, deal type, stage of development, therapy type
Targeted Drug Delivery Partnering 2009-2014 provides understanding and access to the targeted partnering deals and agreements entered into by the world’s leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter targeted drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 180 links to online copies of actual targeted drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of targeted drug delivery dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in targeted drug delivery dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into targeted drug delivery dealmaking.
Chapter 3 provides a review of the leading targeted drug delivery deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of targeted drug delivery partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in targeted drug delivery partnering and dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about targeted drug delivery partnering in the research, development and commercialization of drug delivery technologies and products.
Targeted Drug Delivery Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to targeted drug delivery trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in targeted drug delivery dealmaking in the biopharma industry since 2009
- Access to summary headline, upfront, milestone and royalty data
- Access to over 130 targeted drug delivery contract documents
- The leading targeted drug delivery deals by value since 2009
In Targeted Drug Delivery Partnering 2009-2014, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Therapy type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Targeted Drug Delivery Partnering 2009-2014 provides the reader with the following key benefits:
- In-depth understanding of targeted drug delivery deal trends since 2009
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 130 actual deal records entered into by the world’s biopharma companies since 2009
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Table of Content
Chapter 1 – Introduction
Chapter 2 – Trends in targeted drug delivery partnering
2.2. Targeted drug delivery partnering over the years
2.3. Big pharma Targeted drug delivery dealmaking activity
2.4. Big biotech Targeted drug delivery dealmaking activity
2.5. Targeted drug delivery partnering by deal type
2.6. Targeted drug delivery partnering industry sector
2.7. Targeted drug delivery partnering by stage of development
2.8. Targeted drug delivery partnering by therapy type
2.9. Disclosed financial deal terms for targeted drug delivery partnering
2.9.1 Targeted drug delivery headline values
2.9.2 Targeted drug delivery upfront payments
2.9.3 Targeted drug delivery milestone payments
2.9.4 Targeted drug delivery royalty rates
Chapter 3 – Leading Targeted drug delivery deals
3.2. Top Targeted drug delivery deals by value
Chapter 4 – Targeted drug delivery dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By therapy type
Central Nervous System
Metabolic & endocrinology
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
List of Chart
Figure 1: Targeted drug delivery partnering since 2009
Figure 2: Big pharma – top 50 – Targeted drug delivery deals 2009 to 2014
Figure 3: Big biotech– top 50 – Targeted drug delivery deals 2009 to 2014
Figure 4: Big pharma Targeted drug delivery deal frequency – 2009 to 2014
Figure 5: Big biotech Targeted drug delivery deal frequency – 2009 to 2014
Figure 6: Targeted drug delivery partnering by deal type since 2009
Figure 7: Targeted partnering by industry sector since 2009
Figure 8: Targeted drug delivery partnering by stage of development since 2009
Figure 9: Targeted drug delivery partnering by therapy type since 2009
Figure 10: Targeted drug delivery deals with a headline value
Figure 11: Targeted drug delivery deals with upfront payment values
Figure 12: Targeted deals with milestone payments
Figure 13: Targeted drug delivery deals with royalty rates, %
Figure 14: Top Targeted drug delivery deals by value since 2009
Figure 15: Online partnering resources
Figure 16: Forthcoming partnering events
Figure 17: Deal type definitions
Make an enquiry before buying this Report
Please fill the enquiry form below.